Friday, 18 Jan 2019

You are here

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.

The study was a double-blind, phase 2, randomised, controlled trial of UST vs. PBO in ANA positive, adult SLE patients with moderate-to-severe disease activity.

Patients were randomly assigned (3:2) to the UST or PBO and were stratified according to skin biopsy, nephritis, baseline medications and SLEDAI-2K scores. 

Patients received weight-based initial intravenous infusions followed by subcutaneous injections of UST 90 mg every 8 weeks or placebo parenterally as well. The primary endpoint was a SLEDAI-2K responder index-4 (SRI-4) response at week 24.

Of the 166 patients screened, 102 were randomly assigned to UST (n=60) or PBO (n=42). The week 24 SRI-4 response rates were:

  • UST - 62%
  • PBO - 33% (p=0·006)

Adverse events were similar between groups (78% vs 67%) as were infections (45%] vs 50%). There were no deaths or opportunistic infections.

These data are encouraging for larger phase III trials studying UST in active SLE patients to proceed.

The study was funed by Janssen Research & Development, LLC.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Nailfold Videocapillaroscopy in Dermatomyositis

A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM. 

TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk

Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM. Based on a meta-analysis, DM cancer risk is five times higher than in the general population and twice that compared with PM cancer risk. 

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma.